Myriad Genetics Inc
MYGN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000899923
No open-market purchases or sales by Myriad Genetics Inc insiders were filed in the last 90 days; 196 institutions reported holding it in 13F filings for Q2 2026, worth $507.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 196
- 13F valueReported value at the end of Q2 2026
- $507.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MYGN, Q2 2026
No superinvestor reported holding MYGN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Myriad Genetics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Kumar RashmiDirector | SSale | −15.0K | $4.46 | −$66.9K | −8.0%171.9K after | 10b5-1 |
| May 14, 2026 (view filing) | May 14 | Same day | Bisaro PaulDirector | PPurchase | +7.50K | $3.69 | +$27.7K | +8.3%97.4K after | |
| Mar 9, 2026 (view filing) | Mar 9 | Same day | Raha Samraat S.President and CEO | PPurchase | +40.0K | $5.00 | +$200.0K | +8.8%493.1K after | |
| Feb 27, 2026 (view filing) | Feb 25-27 | 2 days | Phanstiel S. LouiseDirector | PPurchase | +104.5K | $4.73 | +$494.5K | +58.9%282.0K after | 3 lots |
| Oct 11, 2024 (view filing) | Oct 11 | Same day | Diaz Paul JPresident and CEO | SSale | −15.0K | $22.93 | −$343.9K | −1.5%962.4K after | 10b5-1 |
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Muzzey DaleChief Scientific Officer | SSale | −2.10K | $26.17 | −$55.0K | −1.9%108.0K after | |
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Diaz Paul JPresident and CEO | SSale | −15.0K | $26.72 | −$400.8K | −1.5%977.4K after | 10b5-1 |
| Sep 9, 2024 (view filing) | Sep 9 | Same day | Dreismann HeinrichDirector | SSale | −10.0K | $27.05 | −$270.5K | −7.6%121.6K after | |
| Sep 4, 2024 (view filing) | Sep 3 | 1 day | Reitan Colleen FDirector | SSale | −46.0K | $27.95 | −$1.29M | −52.0%42.5K after | 10b5-1 |
| Aug 23, 2024 (view filing) | Aug 21 | 2 days | Ancona MargaretSVP, Chief of Staff | SSale | −11.5K | $27.82 | −$321.0K | −12.7%79.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Myriad Genetics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,890,440 | $62.2M | 0.00% | +2,000,796+22.5% | Added |
| Millennium Management LLC | 6,620,372 | $37.8M | 0.03% | −48,445−0.7% | Reduced |
| Vestal Point Capital, LP | 5,735,000 | $32.7M | 0.77% | +4,087,000+248.0% | Added |
| State Street Corp | 4,985,060 | $28.5M | 0.00% | +561,033+12.7% | Added |
| D. E. Shaw & Co., Inc. | 4,582,083 | $26.2M | 0.02% | +82,359+1.8% | Added |
| Vanguard Capital Management LLC | 4,081,376 | $23.3M | 0.00% | +156,851+4.0% | Added |
| Acadian Asset Management LLC | 3,126,973 | $17.8M | 0.02% | +818,384+35.4% | Added |
| Vanguard Portfolio Management LLC | 3,079,670 | $17.6M | 0.00% | +497,439+19.3% | Added |
| AQR Capital Management LLC | 2,766,689 | $15.8M | 0.01% | +854,393+44.7% | Added |
| Morgan Stanley | 2,481,104 | $14.2M | 0.00% | −687,638−21.7% | Reduced |